Recent CSBR Stock Price | CSBR Stock Predictions | |
$4.90 | -100.00% |
$0.00 |
Recent CSBR Analyst Ratings Breakdown, Making CSBR Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 0 | 0 | 0 | 0 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 2 | 1 | 1 | 1 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 3.0 | 3.0 | 3.0 | 3.0 |
For the CSBR stock predictions from the analysts covering Champions Oncology Inc, we have collected all of the individual CSBR stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the different analysts covering CSBR (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since CSBR stock predictions may vary widely, another useful metric to consider is the median CSBR stock prediction, which represents the price at which half of the analysts
made CSBR stock predictions that were higher and half made CSBR stock predictions that were lower. This makes for a different take on the CSBR stock predictions out there, as compared to average or mean.
And that median across all the individual CSBR stock predictions was: $ as of 2024-03-29.
The very highest of the CSBR stock predictions for one year price target was $, while the very lowest of the CSBR stock predictions in the analyst group was
$ (with a standard deviation of $). Get the latest Zacks research report on CSBR — FREE
Find out: CSBR next earnings date »
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
OCFC Stock Predictions
MAXR Stock Predictions
NS Stock Predictions
HMLP Stock Predictions
MTH Stock Predictions
IMMR Stock Predictions
CVU Stock Predictions
BPY Stock Predictions
BIGC Stock Predictions
|
|
Hold (2.00 out of 4) 0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |